Literature DB >> 7677463

Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus.

W J Pories1, M S Swanson, K G MacDonald, S B Long, P G Morris, B M Brown, H A Barakat, R A deRamon, G Israel, J M Dolezal.   

Abstract

OBJECTIVE: This report documents that the gastric bypass operation provides long-term control for obesity and diabetes. SUMMARY BACKGROUND DATA: Obesity and diabetes, both notoriously resistant to medical therapy, continue to be two of our most common and serious diseases.
METHODS: Over the last 14 years, 608 morbidly obese patients underwent gastric bypass, an operation that restricts caloric intake by (1) reducing the functional stomach to approximately 30 mL, (2) delaying gastric emptying with a c. 0.8 to 1.0 cm gastric outlet, and (3) excluding foregut with a 40 to 60 cm Roux-en-Y gastrojejunostomy. Even though many of the patients were seriously ill, the operation was performed with a perioperative mortality and complication rate of 1.5% and 8.5%, respectively. Seventeen of the 608 patients (< 3%) were lost to follow-up.
RESULTS: Gastric bypass provides durable weight control. Weights fell from a preoperative mean of 304.4 lb (range, 198 to 615 lb) to 192.2 lb (range, 104 to 466) by 1 year and were maintained at 205.4 lb (range, 107 to 512 lb) at 5 years, 206.5 lb (130 to 388 lb) at 10 years, and 204.7 lb (158 to 270 lb) at 14 years. The operation provides long-term control of non-insulin-dependent diabetes mellitus (NIDDM). In those patients with adequate follow-up, 121 of 146 patients (82.9%) with NIDDM and 150 of 152 patients (98.7%) with glucose impairment maintained normal levels of plasma glucose, glycosylated hemoglobin, and insulin. These antidiabetic effects appear to be due primarily to a reduction in caloric intake, suggesting that insulin resistance is a secondary protective effect rather than the initial lesion. In addition to the control of weight and NIDDM, gastric bypass also corrected or alleviated a number of other comorbidities of obesity, including hypertension, sleep apnea, cardiopulmonary failure, arthritis, and infertility. Gastric bypass is now established as an effective and safe therapy for morbid obesity and its associated morbidities. No other therapy has produced such durable and complete control of diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7677463      PMCID: PMC1234815          DOI: 10.1097/00000658-199509000-00011

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  18 in total

1.  Vitamin E, vitamin B-6, vitamin B-12, and folate status of gastric bypass surgery patients.

Authors:  L M Boylan; H J Sugerman; J A Driskell
Journal:  J Am Diet Assoc       Date:  1988-05

2.  Gastrointestinal hormone responses to meals before and after gastric bypass and vertical banded gastroplasty.

Authors:  J M Kellum; J F Kuemmerle; T M O'Dorisio; P Rayford; D Martin; K Engle; L Wolf; H J Sugerman
Journal:  Ann Surg       Date:  1990-06       Impact factor: 12.969

3.  Influence of obesity, impaired glucose tolerance, and NIDDM on LDL structure and composition. Possible link between hyperinsulinemia and atherosclerosis.

Authors:  H A Barakat; J W Carpenter; V D McLendon; P Khazanie; N Leggett; J Heath; R Marks
Journal:  Diabetes       Date:  1990-12       Impact factor: 9.461

4.  Insulin receptor kinase in human skeletal muscle from obese subjects with and without noninsulin dependent diabetes.

Authors:  J F Caro; M K Sinha; S M Raju; O Ittoop; W J Pories; E G Flickinger; D Meelheim; G L Dohm
Journal:  J Clin Invest       Date:  1987-05       Impact factor: 14.808

5.  Decreased expression of glucose transporter in muscle from insulin-resistant patients.

Authors:  G L Dohm; C W Elton; J E Friedman; P F Pilch; W J Pories; S M Atkinson; J F Caro
Journal:  Am J Physiol       Date:  1991-03

6.  An in vitro human muscle preparation suitable for metabolic studies. Decreased insulin stimulation of glucose transport in muscle from morbidly obese and diabetic subjects.

Authors:  G L Dohm; E B Tapscott; W J Pories; D J Dabbs; E G Flickinger; D Meelheim; T Fushiki; S M Atkinson; C W Elton; J F Caro
Journal:  J Clin Invest       Date:  1988-08       Impact factor: 14.808

Review 7.  Glucagonlike peptide 1: a newly discovered gastrointestinal hormone.

Authors:  J J Holst
Journal:  Gastroenterology       Date:  1994-12       Impact factor: 22.682

8.  Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes. A longitudinal interventional study.

Authors:  S D Long; K O'Brien; K G MacDonald; N Leggett-Frazier; M S Swanson; W J Pories; J F Caro
Journal:  Diabetes Care       Date:  1994-05       Impact factor: 19.112

9.  Okadaic acid, vanadate, and phenylarsine oxide stimulate 2-deoxyglucose transport in insulin-resistant human skeletal muscle.

Authors:  J O Carey; J L Azevedo; P G Morris; W J Pories; G L Dohm
Journal:  Diabetes       Date:  1995-06       Impact factor: 9.461

10.  Alterations in low-density lipoproteins in subjects with abdominal adiposity.

Authors:  L H Peeples; J W Carpenter; R G Israel; H A Barakat
Journal:  Metabolism       Date:  1989-10       Impact factor: 8.694

View more
  612 in total

1.  Treatment for morbid obesity.

Authors:  A R Carmichael
Journal:  Postgrad Med J       Date:  1999-01       Impact factor: 2.401

2.  A critical look at laparoscopic adjustable silicone gastric banding for surgical treatment of morbid obesity: does it measure up?

Authors:  E J DeMaria; H J Sugerman
Journal:  Surg Endosc       Date:  2000-08       Impact factor: 4.584

3.  The emerging science of body weight regulation and its impact on obesity treatment.

Authors:  Judith Korner; Louis J Aronne
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

4.  Predictors of Remission of T2DM and Metabolic Effects after Laparoscopic Roux-en-y Gastric Bypass in Obese Indian Diabetics-a 5-Year Study.

Authors:  Aparna Govil Bhasker; Carlyne Remedios; Payal Batra; Amit Sood; Shehla Shaikh; Muffazal Lakdawala
Journal:  Obes Surg       Date:  2015-07       Impact factor: 4.129

5.  Evolution of type 2 diabetes mellitus in non morbid obese gastrectomized patients with Roux en-Y reconstruction: retrospective study.

Authors:  Enrique Lanzarini; Attila Csendes; Hans Lembach; Juan Molina; Luis Gutiérrez; Johanna Silva
Journal:  World J Surg       Date:  2010-09       Impact factor: 3.352

6.  Metabolic laparoscopic gastric bypass for obese patients with type 2 diabetes.

Authors:  Mário Nora; Marta Guimarães; Rui Almeida; Paulo Martins; Gil Gonçalves; Maria José Freire; Tiago Ferreira; Cláudia Freitas; Mariana P Monteiro
Journal:  Obes Surg       Date:  2011-11       Impact factor: 4.129

7.  Adaptation of Intestinal and Bile Acid Physiology Accompany the Metabolic Benefits Following Ileal Interposition in the Rat.

Authors:  Ping Zhao; Donna Wendt; Sean Z Goodin; Shwetha Ravichandran; Tara E Chouinard; April D Strader
Journal:  Obes Surg       Date:  2018-03       Impact factor: 4.129

8.  Learning curve for laparoscopic Roux-en-Y gastric bypass with totally hand-sewn anastomosis: analysis of first 600 consecutive patients.

Authors:  C Ballesta-López; I Poves; M Cabrera; J A Almeida; G Macías
Journal:  Surg Endosc       Date:  2005-03-08       Impact factor: 4.584

9.  Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease.

Authors:  Francesco Rubino; Jacques Marescaux
Journal:  Ann Surg       Date:  2004-01       Impact factor: 12.969

10.  Effect of gastric bypass combined with ileal transportation on type 2 diabetes mellitus.

Authors:  Zhaoxia Gao; Bin Wang; Xiaojun Gong; Chun Yao; Defa Ren; Liwei Shao; Yan Pang; Jinxiu Liu
Journal:  Exp Ther Med       Date:  2018-03-06       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.